26th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress. October 13-16, 2026 – Marriott Marquis, New York City

Transplant, Oral Therapy, and MRD: The Clinical Questions Driving Leukemia Day at LL&M 2026

The Lymphoma, Leukemia & Myeloma (LL&M) Congress opens Tuesday, October 13, in New York City with a full morning on the acute leukemias. The session descriptions published in the HMP Global agenda show measurable residual disease (MRD) as the common thread running through nearly every clinical talk of the day.

The program begins with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr. Michal Bar-Natan will review tyrosine kinase inhibitor (TKI) selection and sequencing, including recent data on ponatinib and asciminib in both frontline and relapsed disease. The session will also examine combinations of TKIs with blinatumomab and other immunotherapies intended to deepen molecular responses while limiting chemotherapy exposure, along with new evidence that questions routine allogeneic transplant in first remission for patients who achieve sustained MRD negativity. A companion talk will compare flow cytometry with next-generation sequencing for MRD assessment in adult ALL and address which time points carry the most prognostic weight.

Acute myeloid leukemia (AML) follows. Dr. Gail Roboz will examine results from ASCERTAIN-V, which established oral decitabine/cedazuridine plus venetoclax as a frontline option for older patients and those ineligible for intensive chemotherapy. Her talk covers patient selection, adherence, drug interactions, early bone marrow assessment, and management of myelosuppression and infection, as well as emerging all-oral triplets that add menin inhibitors.

Dr. Pinkal Desai then takes up whether to proceed with allogeneic hematopoietic cell transplantation after remission. According to the agenda, her case-based talk will integrate MRD, genomic profiling, and patient-specific factors, and will cover maintenance with FLT3 and IDH inhibitors, outcomes with reduced-intensity conditioning, and the potential for targeted therapies to delay or obviate transplant in older or unfit patients.

Dr. Madhu Ouseph rounds out the AML block with MRD in daily practice, reviewing next-generation sequencing and multiparameter flow cytometry across AML and ALL, the emerging use of MRD as a surrogate endpoint in clinical trials, and practical problems that include assay standardization, timing of assessment, and the interpretation of low-level positivity.

The afternoon turns to the myeloproliferative neoplasms, where Dr. John Mascarenhas will discuss when to adjust, switch, or continue therapy in myelofibrosis, including the evolving role of JAK inhibitors, suboptimal response, treatment-related cytopenias, molecular risk stratification, and the timing of transplant considerations.

Reference

HMP Global. Agenda. Lymphoma, Leukemia & Myeloma Congress 2026. New York, NY, October 13-16, 2026. Accessed October 10, 2026. https://www.hmpglobalevents.com/llmcongress/agenda